View Financial HealthSartorius 配当と自社株買い配当金 基準チェック /06Sartorius配当を支払う会社であり、現在の利回りは0.32%です。主要情報0.3%配当利回り-0.004%バイバック利回り総株主利回り0.3%将来の配当利回り0.4%配当成長9.6%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向33%最近の配当と自社株買いの更新お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).すべての更新を表示Recent updatesお知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.お知らせ • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.お知らせ • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025お知らせ • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025お知らせ • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025お知らせ • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.お知らせ • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024お知らせ • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024お知らせ • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.お知らせ • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.お知らせ • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.お知らせ • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023お知らせ • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023Reported Earnings • Jul 23Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: €2.42. Revenue: €1.04b (up 24% from 2Q 2021). Net income: €165.8m (up 53% from 2Q 2021). Profit margin: 16% (up from 13% in 2Q 2021). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 13%, compared to a 7.9% growth forecast for the industry in Germany.Price Target Changed • Jul 22Price target decreased to €404Down from €444, the current price target is an average from 17 analysts. New target price is approximately in line with last closing price of €394. Stock is down 17% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year.Price Target Changed • Jul 12Price target decreased to €416Down from €470, the current price target is an average from 17 analysts. New target price is 12% above last closing price of €372. Stock is down 23% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year.Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to €364, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total returns to shareholders of 123% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €229 per share.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €308, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 87% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €447 per share.Buying Opportunity • Jun 01Now 21% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).Reported Earnings • Feb 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jan 19Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €383, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 35x in the Medical Equipment industry in Germany. Total returns to shareholders of 288% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share.Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020).Price Target Changed • Jul 26Price target increased to €383Up from €355, the current price target is an average from 17 analysts. New target price is 19% below last closing price of €473. Stock is up 75% over the past year.Reported Earnings • Jul 24Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • Apr 24First quarter 2021 earnings released: EPS €1.20The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue.Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).Price Target Changed • Feb 22Price target raised to €331Up from €247, the current price target is an average from 16 analysts. The new target price is 25% below the current share price of €442. As of last close, the stock is up 117% over the past year.Reported Earnings • Feb 21Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 30New 90-day high: €366The company is up 13% from its price of €323 on 30 October 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €202 per share.Price Target Changed • Nov 25Price target raised to €247Up from €217, the current price target is an average from 16 analysts. The new target price is 25% below the current share price of €329. As of last close, the stock is up 98% over the past year.Is New 90 Day High Low • Oct 22New 90-day high: €333The company is up 24% from its price of €269 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €174 per share.Is New 90 Day High Low • Sep 29New 90-day high: €297The company is up 18% from its price of €251 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share.決済の安定と成長配当データの取得安定した配当: SRTはGerman市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。増加する配当: SRTはGerman市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。配当利回り対市場Sartorius 配当利回り対市場SRT 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SRT)0.3%市場下位25% (DE)1.5%市場トップ25% (DE)4.5%業界平均 (Life Sciences)0.8%アナリスト予想 (SRT) (最長3年)0.4%注目すべき配当: SRTの配当金 ( 0.32% ) はGerman市場の配当金支払者の下位 25% ( 1.54% ) と比べると目立ったものではありません。高配当: SRTの配当金 ( 0.32% ) はGerman市場の配当金支払者の上位 25% ( 4.55% ) と比較すると低いです。株主への利益配当収益カバレッジ: SRT German市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: SRT German市場において目立った配当金を支払っていません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 06:48終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sartorius Aktiengesellschaft 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Charles PitmanBarclaysCharles PitmanBarclaysHarry GillisBerenberg35 その他のアナリストを表示
お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.
お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.
Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).
Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).
お知らせ • Feb 17Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time.
お知らせ • Feb 07Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026.
お知らせ • Feb 05Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division.
お知らせ • Jan 28Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026
お知らせ • Jan 16Sartorius Expands Bio-Circular Product Offering for More Sustainable BioprocessesSartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network.
お知らせ • Dec 19+ 3 more updatesSartorius Aktiengesellschaft to Report Q1, 2026 Results on Apr 23, 2026Sartorius Aktiengesellschaft announced that they will report Q1, 2026 results on Apr 23, 2026
お知らせ • Oct 17Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%.
お知らせ • Jun 23+ 1 more updateSartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)Sartorius Aktiengesellschaft(XTRA:SRT) dropped from FTSE All-World Index (USD)
お知らせ • Apr 17Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively.
お知らせ • Mar 29Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025.
お知らせ • Feb 18Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025.
お知らせ • Feb 09Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025.
お知らせ • Jan 28+ 1 more updateSartorius Aktiengesellschaft to Report Nine Months, 2025 Results on Oct 16, 2025Sartorius Aktiengesellschaft announced that they will report nine months, 2025 results on Oct 16, 2025
お知らせ • Jan 14+ 1 more updateSartorius Aktiengesellschaft to Report Fiscal Year 2024 Final Results on Feb 17, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 final results on Feb 17, 2025
お知らせ • Nov 16Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025
お知らせ • Sep 19Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3).Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin. Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024.
お知らせ • Feb 03Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024
お知らせ • Jan 26+ 2 more updatesSartorius Aktiengesellschaft to Report Q3, 2024 Results on Oct 17, 2024Sartorius Aktiengesellschaft announced that they will report Q3, 2024 results on Oct 17, 2024
お知らせ • Jan 18Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024
お知らせ • Oct 13Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development.
お知らせ • Aug 06+ 1 more updateSartorius Announces Executive Board ChangesSartorius appointed Florian Funck as Member of the Sartorius Executive Board, effective April 1, 2024. Funck succeeds Rainer Lehmann, with whom it was agreed in early May 2023 that he would leave the Executive Board at his own request at the end of October 2023. Funck joins the company from his current role as CFO of the Haniel Group, where he has been working for more than two decades. Funck is also a member of the Supervisory Boards of Vonovia SE and the Haniel holdings TAKKT AG and Ceconomy AG. At Sartorius, in addition to finance, he will also be responsible for the IT and digitalization functions. After Lehmann's departure and until Funck takes over, Sartorius CEO Joachim Kreuzburg will assume the responsibilities on an interim basis.
お知らせ • Jan 27Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth.
お知らせ • Jan 04Sartorius Announces Management Changes for Sartorius North AmericaSartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland.
お知らせ • Oct 20Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023
お知らせ • Oct 19+ 2 more updatesSartorius Aktiengesellschaft to Report Nine Months, 2023 Results on Oct 19, 2023Sartorius Aktiengesellschaft announced that they will report nine months, 2023 results on Oct 19, 2023
Reported Earnings • Jul 23Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: EPS: €2.42. Revenue: €1.04b (up 24% from 2Q 2021). Net income: €165.8m (up 53% from 2Q 2021). Profit margin: 16% (up from 13% in 2Q 2021). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 13%, compared to a 7.9% growth forecast for the industry in Germany.
Price Target Changed • Jul 22Price target decreased to €404Down from €444, the current price target is an average from 17 analysts. New target price is approximately in line with last closing price of €394. Stock is down 17% over the past year. The company is forecast to post earnings per share of €9.55 for next year compared to €4.66 last year.
Price Target Changed • Jul 12Price target decreased to €416Down from €470, the current price target is an average from 17 analysts. New target price is 12% above last closing price of €372. Stock is down 23% over the past year. The company is forecast to post earnings per share of €8.83 for next year compared to €4.66 last year.
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment improved over the past weekAfter last week's 15% share price gain to €364, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total returns to shareholders of 123% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €229 per share.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €308, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total returns to shareholders of 87% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €447 per share.
Buying Opportunity • Jun 01Now 21% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be €448, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings is also forecast to grow by 11% per annum over the same time period.
Upcoming Dividend • Mar 21Upcoming dividend of €1.25 per shareEligible shareholders must have bought the stock before 28 March 2022. Payment date: 30 March 2022. Payout ratio is a comfortable 27% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%).
Reported Earnings • Feb 18Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Revenue: €3.45b (up 48% from FY 2020). Net income: €318.9m (up 41% from FY 2020). Profit margin: 9.2% (in line with FY 2020). Revenue exceeded analyst estimates by 1.5%. Over the next year, revenue is forecast to grow 18%, compared to a 12% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €383, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 35x in the Medical Equipment industry in Germany. Total returns to shareholders of 288% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €292 per share.
Reported Earnings • Oct 22Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: €897.7m (up 44% from 3Q 2020). Net income: €105.6m (up 55% from 3Q 2020). Profit margin: 12% (in line with 3Q 2020).
Price Target Changed • Jul 26Price target increased to €383Up from €355, the current price target is an average from 17 analysts. New target price is 19% below last closing price of €473. Stock is up 75% over the past year.
Reported Earnings • Jul 24Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €838.1m (up 53% from 2Q 2020). Net income: €108.1m (up 219% from 2Q 2020). Profit margin: 13% (up from 6.2% in 2Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS €1.20The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €791.1m (up 55% from 1Q 2020). Net income: €82.0m (up 78% from 1Q 2020). Profit margin: 10% (up from 9.1% in 1Q 2020). The increase in margin was driven by higher revenue.
Upcoming Dividend • Mar 22Upcoming Dividend of €0.70 Per ShareWill be paid on the 31st of March to those who are registered shareholders by the 29th of March. The trailing yield of 0.2% is below the top quartile of German dividend payers (3.3%), and is lower than industry peers (1.0%).
Price Target Changed • Feb 22Price target raised to €331Up from €247, the current price target is an average from 16 analysts. The new target price is 25% below the current share price of €442. As of last close, the stock is up 117% over the past year.
Reported Earnings • Feb 21Full year 2020 earnings released: EPS €3.31 (vs €2.29 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €2.34b (up 28% from FY 2019). Net income: €226.3m (up 44% from FY 2019). Profit margin: 9.7% (up from 8.6% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 30New 90-day high: €366The company is up 13% from its price of €323 on 30 October 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €202 per share.
Price Target Changed • Nov 25Price target raised to €247Up from €217, the current price target is an average from 16 analysts. The new target price is 25% below the current share price of €329. As of last close, the stock is up 98% over the past year.
Is New 90 Day High Low • Oct 22New 90-day high: €333The company is up 24% from its price of €269 on 24 July 2020. The German market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €174 per share.
Is New 90 Day High Low • Sep 29New 90-day high: €297The company is up 18% from its price of €251 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share.